Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kunimoto, Hiroyoshi  [Clear All Filters]
2024
Ohashi T, Kunimoto H, Nukui J, Teshigawara H, Koyama S, Miyazaki T, Hagihara M, Matsumoto K, Koshimizu E, Tsuchida N, et al. A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant. Int J Hematol. 2024.
2023
Kunimoto H, Miura A, Maeda A, Tsuchida N, Uchiyama Y, Kunishita Y, Nakajima Y, Takase-Minegishi K, Yoshimi R, Miyazaki T, et al. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome. Int J Hematol. 2023.
Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, et al. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023.
2021
Murakami K, Kurotaki D, Kawase W, Soma S, Fukuchi Y, Kunimoto H, Yoshimi R, Koide S, Oshima M, Hishiki T, et al. OGT Regulates Hematopoietic Stem Cell Maintenance via PINK1-Dependent Mitophagy. Cell Rep. 2021;34(1):108579.
2020
Kunimoto H, Nakajima H. Clonal hematopoiesis: Molecular basis and clinical relevance. Leuk Res. 2020;98:106457.
Kunimoto H, Fukuchi Y, Murakami K, Ikeda J, Teranaka H, Kato I, Miyazaki T, Enaka M, Mitsuhashi T, Yamazaki E, et al. Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7. Hemasphere. 2020;4(5):e469.